Chemotherapy Induced Peripheral Neuropathy Pipeline | Companies – MediciNova, Asahi Kasei Pharma Corp., AnnJi Pharmaceutical, EA Pharma, Aptinyx, Sonnet Biotherapeutics Holdings, Toray, Solasia Pharma
DelveInsight, a leading market research and consulting firm, has recently published an in-depth report on the Chemotherapy Induced Peripheral Neuropathy pipeline, providing valuable insights into emerging therapies, companies, and future outlooks.
DelveInsight’s, “Chemotherapy Induced Peripheral Neuropathy Pipeline Insight 2023” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Chemotherapy Induced Peripheral Neuropathy pipeline landscape. It covers the Chemotherapy Induced Peripheral Neuropathy pipeline drug profiles, including Chemotherapy Induced Peripheral Neuropathy clinical trials and nonclinical stage products. It also covers the Chemotherapy Induced Peripheral Neuropathy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To explore more information on the latest breakthroughs in the Chemotherapy Induced Peripheral Neuropathy Pipeline treatment landscape of the report, click here @ Chemotherapy Induced Peripheral Neuropathy Pipeline Outlook
Key Takeaways from the Chemotherapy-Induced Peripheral Neuropathy Pipeline Report
- DelveInsight’s Chemotherapy Induced Peripheral Neuropathy Pipeline report depicts a robust space with 13+ active players working to develop 13+ pipeline therapies for Chemotherapy Induced Peripheral Neuropathy.
- The leading Chemotherapy Induced Peripheral Neuropathy Companies include MediciNova, Asahi Kasei Pharma Corp., AnnJi Pharmaceutical, EA Pharma, Aptinyx, Sonnet Biotherapeutics Holdings, Toray, Solasia Pharma, Enveric Biosciences, Regenacy Pharmaceuticals, NeuroBo Pharmaceuticals, and others
- Promising Chemotherapy Induced Peripheral Neuropathy Pipeline Therapies include Targin, sodium selenite pentahydrate, Normal saline, Chemotherapy, Acetylcarnitine, Cesamet™ (nabilone), Pregabalin, and others
- In April 2022, Wex Pharmaceuticals Inc. initiated a randomized, double-blind, placebo controlled,multicenter, efficacy and safety trial of single cycle Tetrodotoxin in the treatment of Chemotherapy Induced NeuropathicPain. The trial period will comprise a Screening Period (up to 35 Days), a two-week period for the determinations ofBaseline pain followed by randomization and 4-day treatment, followed by a 12-week follow up period (12 weeks totalafter initial treatment), and an End-of-Trial/Follow-up visit, which will occur at Week 13. This is a study to research theeffects of the study drug on neuropathic pain compared placebo.
- E-52862 (MR309) developed by Esteve is a selective σ1R antagonist currently undergoing Phase II clinical trials for neuropathic pain and represents a potential first-in-class analgesic. E-52862 shows high σ1R affinity and selectivity. It binds to σ1R in the CNS when administered systemically, as shown by autoradiographic ex vivo binding assays in mice, and its efficacy correlates with the occupancy of σ1Rs. E-52862 has completed single- and multiple-dose phase I clinical studies demonstrating good safety, tolerability, and pharmacokinetic profiles in humans, and is currently in Phase II clinical trials for the treatment of neuropathic pain of different etiology using a daily oral dose of 400 mg in Europe.
For further information, refer to the detailed Chemotherapy Induced Peripheral Neuropathy Unmet Needs, Chemotherapy Induced Peripheral Neuropathy Market Drivers, and Chemotherapy Induced Peripheral Neuropathy Market Barriers, click here for Chemotherapy Induced Peripheral Neuropathy Ongoing Clinical Trial Analysis
Chemotherapy Induced Peripheral Neuropathy Overview
Chemotherapy-induced painful neuropathy (CIPN) is a predominantly sensory neuropathy that may be accompanied by motor and autonomic changes. CIPN is a major dose-limiting side effect of several first-line chemotherapeutic agents. The symptoms of CIPN include tingling, pain, decreased sensation, increased sensitivity to touch, temperature, pressure, pain; muscle weakness, and/or irreversible nerve damage.
Request a sample and discover the recent advances in Chemotherapy Induced Peripheral Neuropathy Ongoing Clinical Trial Analysis and Medications, click here @ Chemotherapy Induced Peripheral Neuropathy Treatment Landscape
Chemotherapy Induced Peripheral Neuropathy Emerging Drugs Profile
- MN-166 (ibudilast): MediciNova
MN-166 (ibudilast) is a first-in-class, orally bioavailable, small molecule macrophage migration inhibitory factor inhibitor and phosphodiesterase (PDE) -4 and -10 inhibitor that suppresses pro-inflammatory cytokines and promotes neurotrophic factors. MN-166 (ibudilast)’s anti-neuroinflammatory and neuroprotective actions have been demonstrated in preclinical and clinical studies and the molecule is currently under Phase II development for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) (CIPN).
- ART-123: Asahi Kasei Pharma Corp.
ART-123, a recombinant human soluble thrombomodulin composed of the extracellular domain of thrombomodulin. The drug is in Phase II clinical studies for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN), and solid tumors. In 2008, ART-123 was approved for the treatment of disseminated intravascular coagulation (DIC) in Japan.
Dive deep into rich insights for drugs for Chemotherapy Induced Peripheral Neuropathy Market Drivers and Chemotherapy Induced Peripheral Neuropathy Market Barriers, click here @ Chemotherapy Induced Peripheral Neuropathy Unmet Needs and Analyst Views
Chemotherapy Induced Peripheral Neuropathy Pipeline Therapeutics Assessment
There are approx. 13+ key companies which are developing the therapies for Chemotherapy Induced Peripheral Neuropathy (CIPN). The companies which have their Chemotherapy Induced Peripheral Neuropathy (CIPN) drug candidates in the most advanced stage, i.e. Phase II include, MediciNova.
Scope of the Chemotherapy Induced Peripheral Neuropathy Pipeline Therapeutics Assessment
- Coverage- Global
- Chemotherapy Induced Peripheral Neuropathy Companies- MediciNova, Asahi Kasei Pharma Corp., AnnJi Pharmaceutical, EA Pharma, Aptinyx, Sonnet Biotherapeutics Holdings, Toray, Solasia Pharma, Enveric Biosciences, Regenacy Pharmaceuticals, NeuroBo Pharmaceuticals, and others
- Chemotherapy Induced Peripheral Neuropathy Pipeline Therapies- Targin, sodium selenite pentahydrate, Normal saline, Chemotherapy, Acetylcarnitine, Cesamet™ (nabilone), Pregabalin, and others
- Chemotherapy Induced Peripheral Neuropathy Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Chemotherapy Induced Peripheral Neuropathy Mergers and acquisitions, Chemotherapy Induced Peripheral Neuropathy Licensing Activities @ Chemotherapy Induced Peripheral Neuropathy Emerging Drugs, and Recent Trends
Table of Content
- Introduction
- Executive Summary
- Chemotherapy Induced Peripheral Neuropathy (CIPN): Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Chemotherapy Induced Peripheral Neuropathy (CIPN) – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- MN-166 (ibudilast): MediciNova
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- EA-4017: EA Pharma
- Drug profiles in the detailed report…..
- Preclinical/Discovery Stage Products
- Research programme: cannabidiol-combination therapies: Enveric Biosciences
- Drug profiles in the detailed report…..
- Inactive Products
- Chemotherapy Induced Peripheral Neuropathy (CIPN) Key Companies
- Chemotherapy Induced Peripheral Neuropathy (CIPN) Key Products
- Chemotherapy Induced Peripheral Neuropathy (CIPN)- Unmet Needs
- Chemotherapy Induced Peripheral Neuropathy (CIPN)- Market Drivers and Barriers
- Chemotherapy Induced Peripheral Neuropathy (CIPN)- Future Perspectives and Conclusion
- Chemotherapy Induced Peripheral Neuropathy (CIPN) Analyst Views
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
